ArticleCancer discovery2020
Chromatin Regulator CHD1 Remodels the Immunosuppressive Tumor Microenvironment in PTEN-Deficient Prostate Cancer.
Open access · greenAbstract read
In one paragraph
Article in Cancer discovery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers.
0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed
5.1field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed, 102 citations in OpenAlex.
- Ineffectiveness of immune checkpoint inhibitors in prostate cancer: is it just a question of '-mabs'?The Journal of pathology · 2026Review
- Dual Functions of B7-H3-MAPK Signaling Orchestrate Tumor Immunosuppression via Regulating the Plasticity of Myeloid-derived Suppressor Cells and Fibroblasts.Cancer discovery · 2026Article
- The roles of chromatin remodeling and 3D genome organization in cancers: from mechanistic insights to emerging treatment options.Molecular cancer · 2026Review
- CHD6 promotes triple-negative breast cancer progression and is associated with PI3K/AKT and MAPK pathways.International journal of clinical oncology · 2026Article
- Hypoxia-induced mechanism of TNBC promoting tumour cell proliferation through exosomal miRNA.Mammalian genome : official journal of the International Mammalian Genome Society · 2026Article
- Divergent roles of SPOP and CHD1 in ACSL4 regulation reveal context-dependent vulnerabilities for targeting ferroptosis.Nature communications · 2026Article
- Role of CHD chromatin remodelers in heart development.World journal of pediatrics : WJP · 2026Review
- Development of High-Affinity CHD1 Chromodomain Inhibitors.Journal of medicinal chemistry · 2026Article
- Targeting conserved domains of hypoxia-inducible factors for cancer therapy.The Journal of experimental medicine · 2026Article
- Game of clones: decipher lineage plasticity in hormone-driven cancers.Cellular and molecular life sciences : CMLS · 2026Review
- Genomic landscape and precision therapy in prostate cancer: current status and future directions.NPJ precision oncology · 2026Review
- Genetic loss of CHD1 regulates distinct histone post-translational modifications in the development of castration-resistant prostate cancer.Neoplasia (New York, N.Y.) · 2026Article
- Alterations in AR-FOXA1 signaling in prostate cancer progression and therapeutic resistance.Journal of the National Cancer Center · 2026Review
- CRISPR screens in the context of immune selection identify CHD1 and MAP3K7 as mediators of cancer immunotherapy resistance.Cell reports. Medicine · 2026Article
- Immune Infiltration-Related Genes as Potential Biomarkers and Predicted Targets for Renal Allograft Delayed Graft Function and Survival Outcome: An Integrated Machine Learning Approach and Drugs Analysis.Mediators of inflammation · 2026Article
- Dysregulated NK-cell gene expression defines the enduring symptoms of long COVID-19.Frontiers in immunology · 2026Article
- Tumor microenvironment-induced epigenetic reprogramming of Tregs and its impact on immunotherapy.Frontiers in genetics · 2026Review
- GWAS Identifies SNPs Associated With Severe Adverse Events and Efficacy in Advanced Renal Cell Carcinoma Treated With Nivolumab.Cancer science · 2025Article
- Integrated single-cell, spatial, and bulk transcriptomics reveal a chromatin regulator-TME prognostic framework guiding precision therapy in cervical cancer.Journal of translational medicine · 2025Article
- From intracellular drivers to immune modulators: emerging paradigms in oncogenic pathway-directed immunotherapy optimization.Cell communication and signaling : CCS · 2025Review
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 3 institutions in 1 country.
Di Zhao *Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Li Cai *Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Xin Lu *Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Xin LiangDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jiexi LiDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-6786-0705
Peiwen ChenDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Michael IttmannDepartment of Pathology, Baylor College of Medicine, Houston, Texas.
Xiaoying ShangDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Shan JiangDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Haoyan LiDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-6786-0705
Chenling MengDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Ivonne FloresDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jian H SongDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
James W HornerDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Zhengdao LanDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Chang-Jiun WuDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-8350-6397
Jun LiDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-6786-0705
Qing ChangInstitute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Ko-Chien ChenDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Guocan WangDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Pingna DengDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Denise J SpringDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-4593-0901
Y Alan WangDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas. rdepinho@mdanderson.org yalanwang@mdanderson.org.
Ronald A DePinhoDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas. rdepinho@mdanderson.org yalanwang@mdanderson.org.ORCID 0000-0002-5625-577X
The University of Texas MD Anderson Cancer Center · USBaylor College of Medicine · USUniversity of Notre Dame · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MTargeting Tumor Microenvironment-Induced Therapy Resistance in Prostate Cancer Bone MetastasisP50CA140388 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI THOMPSON, TIMOTHY CHARLES · 2009 to 2022
$23.4MDetermine the Role of Histone Methyltransferase ASH1L in Metastatic Prostate CancerR01CA278889 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Di Zhao · 2024 to 2026
$2.7MDeveloping Novel Therapeutic Approaches Targeting Macrophages in GBMR01CA231349 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WANG, Y. ALAN · 2019 to 2024
$1.8MNovel Therapeutic Approaches Targeting Tumor Suppressor Deficiencies in Advanced Prostate CancerR00CA226360 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ZHAO, DI · 2019 to 2021
$746kMDSC-Tumor Crosstalk in Prostate Cancer Progression and Castration ResistanceR00CA194289 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WANG, GUOCAN · 2018 to 2020
$702kNovel Therapeutic Approaches Targeting Tumor Suppressor Deficiencies in Advanced Prostate CancerK99CA226360 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ZHAO, DI · 2018 to 2018
$92kNCI NIH HHS K99 CA226360NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA140388NCI NIH HHS R00 CA194289NCI NIH HHS R00 CA226360NCI NIH HHS R01 CA231349NCI NIH HHS R01 CA278889
Abstract
Genetic inactivation of
Indexed as
AnimalsCell Line, TumorDisease Models, AnimalDNA-Binding ProteinsGene Expression Regulation, NeoplasticHumansMaleMice, TransgenicProstatic NeoplasmsPTEN PhosphohydrolaseSmad4 ProteinTumor EscapeTumor MicroenvironmentChd1 protein, mouseDNA-Binding ProteinsPTEN PhosphohydrolasePten protein, mouseSmad4 ProteinSmad4 protein, mouse
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.